A study from the University of Cincinnati School of Medicine at the Annual Cancer Symposium on Surgical Oncology in Chicago on March 24, 2018 showed that adjuvant or additional treatment after surgical resection of rare types of gastrointestinal tumors does not improve patients ’ Survival rate. These findings provide in-depth insights into the treatment options for these types of cancer patients, and may no longer require prescribed adjuvant therapy, maintain quality of life, and save money.
I denne undersøgelse brugte forskerne tumordata fra stadium I til III patienter med kirurgisk fjernet ampulla fra 1998 til 2006 (5,298 patienter) i National Cancer Database fra American College of Surgeons til kun at sammenligne kirurgi (3,785), kirurgi plus patienter med yderligere kemoterapi (316) og dem, der skulle opereres plus yderligere kemoterapi og strålebehandling (1,197), blev analyseret for samlet overlevelse.
29% (1,513) of patients who underwent surgical resection of ampullary tumorer received adjuvant therapy. Adjuvant therapy is more commonly used in patients with stage III, lymph node tumors, and positive surgical margins. However, there was no significant difference in stage-specific survival rates among patients with stage I, II, or III receiving any treatment. Similarly, patients with lymph node tumors and positive surgical margins received no adjuvant survival benefit. This national analysis showed that even for patients with aggressive disease, the adjuvant treatment of surgically removed ampullary tumors did not show any survival benefit.
Derfor, uanset hvilken form for kræft, enhver kræft, der har udviklet sig, er det nødvendigt at evaluere undertyperne af kræft og deres forskelle på cellulært niveau. Kun gennem genetisk testning kan vi bestemme patienters molekylære niveauændringer og vejlede mere præcis behandling. Multi-platform atlas-analysen af USA (den autoritative lægemiddelvirksomhed for kræftvejledning i USA) kan ikke kun analysere kræftdrivergener på genetisk niveau, men også kombinere RNA- og proteindetektion for at analysere molekylære mekanismer på flere niveauer, omfattende evaluere tumorkarakteristika og udførligt vejlede symptomatisk medicinering. Mere detaljerede oplysninger kan konsulteres på Global Oncologist Network.
